DK2142570T3 - Anti-EpCam-antistof og anvendelser deraf - Google Patents

Anti-EpCam-antistof og anvendelser deraf

Info

Publication number
DK2142570T3
DK2142570T3 DK08759374.5T DK08759374T DK2142570T3 DK 2142570 T3 DK2142570 T3 DK 2142570T3 DK 08759374 T DK08759374 T DK 08759374T DK 2142570 T3 DK2142570 T3 DK 2142570T3
Authority
DK
Denmark
Prior art keywords
epcam antibody
therapeutic
designated
high affinity
shows high
Prior art date
Application number
DK08759374.5T
Other languages
Danish (da)
English (en)
Inventor
Anna Maria Anastasi
Fiorella Petronzelli
Santis Rita De
Saverio Alberti
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of DK2142570T3 publication Critical patent/DK2142570T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK08759374.5T 2007-04-04 2008-04-02 Anti-EpCam-antistof og anvendelser deraf DK2142570T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07105628 2007-04-04
PCT/EP2008/053913 WO2008122551A2 (en) 2007-04-04 2008-04-02 Anti-epcam antibody and uses thereof

Publications (1)

Publication Number Publication Date
DK2142570T3 true DK2142570T3 (da) 2011-10-03

Family

ID=38458122

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08759374.5T DK2142570T3 (da) 2007-04-04 2008-04-02 Anti-EpCam-antistof og anvendelser deraf

Country Status (21)

Country Link
US (1) US8318911B2 (enExample)
EP (1) EP2142570B1 (enExample)
JP (1) JP5631733B2 (enExample)
KR (1) KR101683884B1 (enExample)
CN (1) CN101970497B (enExample)
AT (1) ATE512988T1 (enExample)
AU (1) AU2008235566B2 (enExample)
BR (1) BRPI0810096A8 (enExample)
CA (1) CA2682296C (enExample)
CY (1) CY1111819T1 (enExample)
DK (1) DK2142570T3 (enExample)
EA (1) EA023679B1 (enExample)
ES (1) ES2367675T3 (enExample)
HR (1) HRP20110620T1 (enExample)
IL (1) IL201196A0 (enExample)
MX (1) MX2009010444A (enExample)
PL (1) PL2142570T3 (enExample)
PT (1) PT2142570E (enExample)
RS (1) RS52040B (enExample)
SI (1) SI2142570T1 (enExample)
WO (1) WO2008122551A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004068110A2 (en) 2003-01-24 2004-08-12 University Of Utah Methods of predicting mortality risk by determining telomere length
ES2433718T3 (es) 2008-12-22 2013-12-12 University Of Utah Research Foundation PCR multiplex monocromática cuantitativa
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
WO2012123755A1 (en) 2011-03-17 2012-09-20 The University Of Birmingham Re-directed immunotherapy
JP6400470B2 (ja) * 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
CN107315086B (zh) * 2011-06-29 2019-09-10 中央研究院 使用表面涂层对生物物质的捕获、纯化和释放
EP2819695B1 (en) * 2012-03-02 2018-06-27 Academia Sinica ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF
US9494500B2 (en) 2012-10-29 2016-11-15 Academia Sinica Collection and concentration system for biologic substance of interest and use thereof
JP6546158B2 (ja) 2013-05-22 2019-07-17 テロメア ダイアグノスティクス インコーポレイテッド 短いテロメアの存在量の測定
TW201623605A (zh) 2014-04-01 2016-07-01 中央研究院 用於癌症診斷及預後之方法及系統
US10112198B2 (en) 2014-08-26 2018-10-30 Academia Sinica Collector architecture layout design
WO2016108954A1 (en) 2014-12-30 2016-07-07 Telomere Diagnostics, Inc. Multiplex quantitative pcr
EP3328897A1 (en) 2015-07-31 2018-06-06 Sutro Biopharma, Inc. ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EPCAM ANTIBODIES
US10107726B2 (en) 2016-03-16 2018-10-23 Cellmax, Ltd. Collection of suspended cells using a transferable membrane
WO2017173091A1 (en) * 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
CN110035768A (zh) 2016-07-26 2019-07-19 泰莎治疗私人有限公司 嵌合抗原受体
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
JP7728701B2 (ja) 2018-12-17 2025-08-25 レビトープ リミテッド 双子型免疫細胞エンゲージャー
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
CN113597432B (zh) * 2019-04-22 2023-05-02 江苏恒瑞医药股份有限公司 抗EpCAM抗体及其应用
CN114026127B (zh) * 2019-06-11 2024-10-29 生物蛋白有限公司 条件活性抗epcam抗体、抗体片段、其免疫缀合物以及其用途
CN110950959B (zh) * 2020-02-25 2020-07-03 和铂医药(上海)有限责任公司 靶向EpCAM的抗体及其制备和应用
CN112094350B (zh) * 2020-06-01 2024-01-05 普众发现医药科技(上海)有限公司 可应用于肿瘤细胞捕获的小鼠抗细胞表面糖蛋白cd326的单克隆抗体
WO2022037323A1 (zh) * 2020-08-19 2022-02-24 上海易慕峰生物科技有限公司 人源化抗体、嵌合抗原受体、核酸、载体、细胞及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US5525338A (en) 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
IT1245748B (it) 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
US5578287A (en) * 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
JP3427871B2 (ja) * 1996-06-24 2003-07-22 戸田工業株式会社 コバルト被着型針状磁性酸化鉄粒子粉末
ITRM20010079A1 (it) 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
US20050180979A1 (en) * 2004-02-13 2005-08-18 Micromet Ag Anti-EpCAM immunoglobulins
US7435804B2 (en) 2004-10-19 2008-10-14 Phage Biotechnology, Inc. Method for obtaining single chain antibodies to human interferon α2b

Also Published As

Publication number Publication date
US20100092491A1 (en) 2010-04-15
CA2682296A1 (en) 2008-10-16
CN101970497B (zh) 2017-05-10
AU2008235566B2 (en) 2013-06-06
BRPI0810096A8 (pt) 2017-12-26
CY1111819T1 (el) 2015-10-07
EA023679B1 (ru) 2016-06-30
EA200970923A1 (ru) 2010-04-30
HRP20110620T1 (hr) 2011-09-30
WO2008122551A3 (en) 2008-12-04
BRPI0810096A2 (pt) 2014-10-21
CN101970497A (zh) 2011-02-09
CA2682296C (en) 2017-02-28
WO2008122551A9 (en) 2009-02-05
US8318911B2 (en) 2012-11-27
JP5631733B2 (ja) 2014-11-26
AU2008235566A1 (en) 2008-10-16
SI2142570T1 (sl) 2012-01-31
PT2142570E (pt) 2011-09-13
RS52040B (sr) 2012-04-30
EP2142570B1 (en) 2011-06-15
KR20100016237A (ko) 2010-02-12
WO2008122551A2 (en) 2008-10-16
EP2142570A2 (en) 2010-01-13
PL2142570T3 (pl) 2011-11-30
ATE512988T1 (de) 2011-07-15
JP2010523096A (ja) 2010-07-15
ES2367675T3 (es) 2011-11-07
KR101683884B1 (ko) 2016-12-07
IL201196A0 (en) 2010-05-17
MX2009010444A (es) 2009-10-20

Similar Documents

Publication Publication Date Title
IL201196A0 (en) Anti-epcam antibody and uses thereof
CY1123400T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
GEP20237480B (en) Antibodies against signal-regulatory protein alpha and methods of use
UA113712C2 (xx) Антитіло до fap і способи його застосування
WO2018170338A3 (en) High affinity mage-a1-specific tcrs and uses thereof
CY1118760T1 (el) Τροποποιημενα αντισωματα εναντι il-23
WO2016210365A3 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
TW200510459A (en) RG1 antibodies and uses thereof
EA201201533A1 (ru) Prlr-специфическое антитело и его применения
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
CY1117236T1 (el) Μονοκλωνικα αντισωματα εναντι γλυπικανης-3
CU20120095A7 (es) Antagonistas de pcsk9
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
AR058325A1 (es) Anticuerpos anti mn y metodos para su utilizacion
BRPI0416141B8 (pt) anticorpo anti-cd52 modificado, composição farmacêutica, vetores de expressão, e método para preparar uma imunoglobulina
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
UA105760C2 (uk) Антитіло проти bst2
CR10143A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer
WO2018183182A8 (en) Methods and compositions for reduction of immunogenicity
EP4512830A3 (en) Antibodies useful in cancer diagnosis
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
WO2018071822A8 (en) ANTIBODIES BINDING TO THE ZIKA VIRUS ENVELOPE PROTEIN AND USES THEREOF
MX2010001237A (es) Nuevos anticuerpos.
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения